Navigation Links
Genes determine the capacity to fight HIV in early stages

The capacity of an individual's immune system to control HIV infection appears to depend on both the specific versions of key immune-system molecules// called HLA Class I that have been inherited, as well as on the fragments of viral protein those molecules display to the T lymphocytes that usually destroy infected cells. In a report in the November issue of PLOS Medicine, researchers from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) report that specific HLA Class I/HIV viral fragment combinations are associated with a more powerful antiviral response, findings that may help develop vaccines against HIV. .

"We found that only a limited number of viral protein fragments from HIV-1 are targeted by the immune system in early infection and that the versions of HLA Class I previously associated with slower HIV-1 disease progression also contribute more to this initial antiviral immune response," says Marcus Altfeld, MD, PhD, of PARC/MGH, the paper's lead author. .

An essential aspect of the immune response involves educating T cells to recognize pathogens or other "non-self" proteins. This is done by means of human leukocyte antigen (HLA) receptors that sit on the surface of virtually every cell. Immune system cells that ingest bacteria or parasites digest those pathogens and display protein fragments on their surface membranes via HLA Class II proteins. Virally infected cells display viral proteins on HLA Class I molecules, which activate the CD8 cytotoxic T lymphocytes that usually destroy infected cells. Although the CD8 response against HIV is ultimately ineffective in protecting infection, several studies have suggested that it plays a key role in determining how quickly the disease progresses after initial infection. .

HLA – also called major histocompatibility complex (MHC) – proteins are also the primary markers of tissues as "self." Unique to each individual, these are the factors that need to be match ed as closely as possible in organ transplants, with perfect matches only possible between identical twins. Some studies have found that HIV patients with particular versions of HLA may be better able to control viral levels, but the diversity of HLA molecules – each person may have up to six different varieties of Class I proteins – has made investigating the role of HLA type in HIV infection challenging.

The current study was designed to determine the contribution of both HLA Class I and the particular viral fragments displayed on those molecules to the activation of HIV-specific CD8 cells. The researchers analyzed blood samples from more than 100 people recently infected with HIV, first determining their specific HLA types by DNA analysis. Then they focused on 173 HIV protein fragments known to bind to those HLA types to see if particular peptides were more powerful in activating the HIV-specific CD8 response. The researchers found that, for many varieties of HLA, only a few HIV protein fragments were responsible for the activation of CD8 T cells early in infection. In addition, the same HLA types that had been previously identified in people who stay healthy for a longer period of time after initial infection were associated with a more powerful early-stage HIV-specific CD8 activity. .

"While we can't say this for sure right now, it is looking like both the HLA Class I molecule and the specific viral sequences being displayed contribute to the strength of immune response against primary HIV infection," says Altfeld. "In addition, the combination of Class I molecules that an individual expresses, something that is genetically determined, seems to have a significant impact on the specificity and strength of that response. .

"Identifying the HIV epitopes [viral fragments] that are particularly good at priming an early T cell response may be important to vaccine design, and the impact of an individual's genetic HLA Class I backg round implies that a successful vaccine would have to overcome genetic factors associated with a less protective response," he adds. Altfeld is an associate professor of Medicine at Harvard Medical School. He and his colleagues are working on a follow-up study with samples from 500 individuals to further investigate the impact of HLA Class I on the control of HIV replication. .

source: EurekAlert

Source-Eurekalert
RM
'"/>




Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Genes for lung disease
3. Genesis of SUPAC
4. Genes for Vision discovered
5. Genes Found To Help Leukemia Treatment
6. Cardiac Valve Disease Linked To Genes
7. Genes Linked To Cigarette Addiction
8. Genes from saliva may predict oral and breast cancer
9. Genes More Important Than Exercise for Bad Cholesterol
10. Genes responsible for social behavior of us
11. Genes to Extend Longevity Discovered
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2017)... ... 2017 , ... From June 20-22, EarQ and Widex held an ... York, where EarQ is headquartered. , Together, the organizations educate hearing care professionals ... consumer, and the latest in hearing technology. At the event, EarQ members got ...
(Date:6/27/2017)... Illinois (PRWEB) , ... June 27, 2017 , ... Two ... were featured in a video designed to encourage lawmakers to protect Medicaid ... National Center for Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking ... studies guidebook. This guidebook offers an excellent branding and exposure opportunity for the ... studies and how-to’s that fall into the following categories:, , ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... P. Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process ... Urbanski offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski ...
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s ... have named Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning Coach ... is decided by NBSCA members who vote to select the coach who embodies the ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
Breaking Medicine Technology: